MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.320
0.000
0.00%
After Hours: 2.320 0 0.00% 16:00 03/02 EST
OPEN
2.290
PREV CLOSE
2.320
HIGH
2.330
LOW
2.215
VOLUME
317.06K
TURNOVER
--
52 WEEK HIGH
3.850
52 WEEK LOW
1.500
MARKET CAP
132.42M
P/E (TTM)
-5.8350
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Kidney Fibrosis Treatment Market Size, Share – Global Trends, Market Demand, Industry Analysis, Growth, Opportunities and Forecast 2025
Mar 01, 2021 (The Expresswire) -- Global Global Kidney Fibrosis Treatment Market report focuses on market Size, Share, status and forecast 2021-2025, along...
The Express Wire · 2d ago
Global Galectin 3 Market 2021 Research Report by Trends, Growth Drivers, Size, Share, Opportunities, Challenges, Risks and Influences Factors Analysis & Forecast to 2027
The Express Wire · 02/15 05:23
What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?
A look at the shareholders of Galectin Therapeutics, Inc. ( NASDAQ:GALT ) can tell us which group is most powerful...
Simply Wall St. · 01/31 07:28
What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?
A look at the shareholders of Galectin Therapeutics, Inc. ( NASDAQ:GALT ) can tell us which group is most powerful...
Simply Wall St. · 01/31 07:28
What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?
A look at the shareholders of Galectin Therapeutics, Inc. ( NASDAQ:GALT ) can tell us which group is most powerful...
Simply Wall St. · 01/31 07:28
Kidney Fibrosis Treatment Market 2021 Overview and Outlook – Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland)
Jan 27, 2021 (Market Insight Reports) -- "Global Kidney Fibrosis Treatment Market Size, Status and Forecast 2021-2027" The New report includes a detailed...
Market Insight Reports · 01/27 11:07
Insider Sells Galectin Therapeutics Stock
 
Benzinga · 01/19 16:15
Insider Sells Galectin Therapeutics Stock
A Form 4 filing filed with the SEC on Tuesday, January 19 showed that Amelio Gilbert F sold 60,000 shares of Galectin Therapeutics Inc (NASDAQ:GALT)at an average price of $2.17. The transaction moved the executive's stake in Galectin Therapeutics Inc. to 6...
Benzinga · 01/19 16:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GALT. Analyze the recent business situations of Galectin Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GALT stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 11.51M
% Owned: 20.16%
Shares Outstanding: 57.08M
TypeInstitutionsShares
Increased
21
440.78K
New
13
148.58K
Decreased
18
336.25K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Non-Executive Chairman/Independent Director
Richard Uihlein
President/Chief Executive Officer/Director
Joel Lewis
Chief Financial Officer/Secretary
Jack Callicutt
Executive Vice President
Eliezer Zomer
Executive Director
Adam Allgood
Other
Pol Boudes
Other
J. Rex Horton
Director
James Czirr
Director
Harold Shlevin
Independent Director
Gilbert Amelio
Independent Director
Kary Eldred
Independent Director
Kevin Freeman
Independent Director
Gilbert Omenn
Independent Director
Marc Rubin
Independent Director
Elissa Schwartz
Independent Director
Richard Zordani
  • Dividends
  • Splits
  • Insider Activity
No Data
About GALT
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.